American Society of Nephrology (ASN) Kidney Week 2025

Houston, Texas 05 November 2025 - 09 November 2025

Tenapanor relieves constipation in ESKD patients with hyperphosphataemia

02 Dec 2025 by

Individuals with end-stage kidney disease (ESKD) who have mild-to-severe constipation obtain relief from tenapanor in the post hoc analysis of the phase III BLOCK study.

Tenapanor relieves constipation in ESKD patients with hyperphosphataemia

02 Dec 2025

Telitacicept reduces proteinuria in adults with IgA nephropathy

29 Nov 2025 by

Treatment with telitacicept led to a significant reduction in proteinuria among patients with immunoglobulin A nephropathy (IgAN) compared with placebo, according to a phase III study presented at ASN Kidney Week 2025.

Telitacicept reduces proteinuria in adults with IgA nephropathy

29 Nov 2025

Sparsentan remains superior to irbesartan for IgAN in post hoc analysis

28 Nov 2025 by

In the post hoc analysis of the phase III PROTECT trial, the non-immunosuppressive dual endothelin angiotensin receptor antagonist sparsentan remains superior to irbesartan for the treatment of immunoglobulin A nephropathy (IgAN).

Sparsentan remains superior to irbesartan for IgAN in post hoc analysis

28 Nov 2025

Conservative dialysis strategy promotes faster kidney function recovery in severe AKI

26 Nov 2025 by

In hospitalized patients with acute kidney injury (AKI) requiring dialysis (AKI-D), a conservative strategy appears to lead to more frequent and faster kidney function recovery with fewer dialysis sessions compared with a conventional strategy, as shown in the LIBERATE-D trial.

Conservative dialysis strategy promotes faster kidney function recovery in severe AKI

26 Nov 2025

Atacicept for IgA nephropathy succeeds in phase III trial

25 Nov 2025 by

Treatment with the self-administered atacicept injectable yields a significant reduction in proteinuria in patients with IgA nephropathy, according to interim data from the phase III ORIGIN 3 trial.

Atacicept for IgA nephropathy succeeds in phase III trial

25 Nov 2025

Tirzepatide may reduce major kidney events in T2D patients with CVD, CKD

25 Nov 2025 by

The use of tirzepatide appears to reduce decline in kidney function, prevent albuminuria progression, and lower the risk of the composite kidney outcome compared with dulaglutide in patients with type 2 diabetes (T2D), atherosclerotic cardiovascular disease (ASCVD), and very high-risk chronic kidney disease (CKD), reports a study presented at Kidney Week 2025.

Tirzepatide may reduce major kidney events in T2D patients with CVD, CKD

25 Nov 2025